BCAB
BioAtla, Inc.0.7601
-0.0122-1.58%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Light Q&A details phase 3 design
Q&A was thin. With just one analyst probing, management filled gaps on OSV's phase 3 design, disclosing ~300 patients for full approval versus an earlier interim for accelerated path—details skipped in prepared remarks—plus stratification by P16 status and local-regional disease. For BA 3182, they confirmed comprehensive dose/schedule data in H1 2026. No new concerns surfaced; answers reaffirmed FDA alignment and progress. Investors note the clear approval roadmap but watch cash burn ahead of partnerships and trial start.
Key Stats
Market Cap
44.69MP/E (TTM)
-Basic EPS (TTM)
-1.15Dividend Yield
0%Recent Filings
8-K
Nasdaq delisting review stayed
Nasdaq's Listing Council called for review the February 6 decision to suspend BioAtla's trading and delist its shares effective February 10, 2026, over $1 minimum bid price and $2.5 million equity shortfalls despite prior MVLS compliance. Trading continues during the weeks-to-months review. No assurance of continued listing.
8-K
Nasdaq delisting determination issued
BioAtla faces Nasdaq delisting after the Hearings Panel cited failure to meet the $1.00 bid price rule and $2.5 million stockholders' equity requirement, despite prior MVLS compliance. Trading suspension hits February 10, 2026, absent a stay; the company requested Listing Council review and plans an appeal. OTC trading looms, likely denting liquidity. $1.25 million remains under PPAs; SEPA sales blocked during suspension.
8-K
Merger replaces failed reverse split
BioAtla scrapped a super-voting preferred stock ploy to approve a reverse stock split after Nasdaq flagged it as a Voting Rights Rule violation, opting instead for a 1-for-50 merger with a subsidiary on January 30, 2026, pending majority common stock vote. Board nixed the split to dodge delisting risk amid Nasdaq compliance battles. Merger sidesteps supermajority hurdle. Secured $5M from Inversagen AI for 4.375% of SPV units.
8-K
Super-voting share issued
BioAtla issued one Super-Voting Share of Series A Junior Preferred Stock to CEO Jay Short for $0.01 on January 9, 2026, enabling approval of the pending reverse stock split if two-thirds of common shares present vote for it. This bolsters efforts after the proposal failed at the January 12 reconvened special meeting, adjourned to January 26. Super-Voting Share locks in CEO sway. Nasdaq compliance hangs in the balance.
8-K
BioAtla secures $40M Oz-V funding
BioAtla inked an Investment Agreement on December 30, 2025, to sell 35% of SPV common units holding Oz-V rights to Inversagen AI for $40 million total. Initial $5 million closes by January 30, 2026; $35 million follows in Q1 2026 tied to Phase 3 OPSCC study start. BioAtla keeps 65% ownership, funds Oz-V trials. Deal with related party.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
AURA
Aura Biosciences, Inc.
6.18-0.15
BCAX
Bicara Therapeutics Inc.
18.15-0.21
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BCYC
Bicycle Therapeutics plc
7.31-0.02
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
ESLA
Estrella Immunopharma, Inc.
1.63-0.18
NXTC
NextCure, Inc.
11.12-0.35
XLO
Xilio Therapeutics, Inc.
0.65+0.00